UB Paderborn / Katalog / Suche / in CDI

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

1 – 25 von 80.915

Sortiert nach

Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

The Lancet (British edition), 2015-07, Vol.386 (9990), p.258-265

2015

Volltextzugriff (PDF)

The predictors of paradoxical reactions, especially psoriasis, to biologic therapy-findings from the TReasure database: a 5-year follow-up study

Rheumatology (Oxford, England), 2023-12, Vol.62 (12), p.3962-3967

2023

Volltextzugriff (PDF)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab

Alimentary pharmacology & therapeutics, 2019-01, Vol.49 (1), p.31-40

2019

Volltextzugriff (PDF)

Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systematic literature review

Seminars in arthritis and rheumatism, 2014-04, Vol.43 (5), p.613-626

2014

Volltextzugriff (PDF)

Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates

Pediatric research, 2017-05, Vol.81 (5), p.692-711

2017

Volltextzugriff (PDF)

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

British journal of dermatology (1951), 2019-12, Vol.181 (6), p.1177-1189

2019

Volltextzugriff (PDF)

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry

British journal of dermatology (1951), 2016-08, Vol.175 (2), p.340-347

2016

Volltextzugriff (PDF)

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.890-901

2017

Volltextzugriff (PDF)

Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy

EJD. European journal of dermatology, 2021-06, Vol.31 (3), p.307-317

2021

Volltextzugriff (PDF)

Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan

PloS one, 2020-12, Vol.15 (12), p.e0244620

2020

Volltextzugriff (PDF)

Short‐term efficacy and safety of new biological agents targeting the interleukin‐23–T helper 17 pathway for moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis

British journal of dermatology (1951), 2017-03, Vol.176 (3), p.594-603

2017

Volltextzugriff (PDF)

Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: A systematic review and meta-analysis

Medicine (Baltimore), 2021-10, Vol.100 (40), p.e27368

2021

Volltextzugriff (PDF)

Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting

Rheumatology (Oxford, England), 2015-07, Vol.54 (7), p.1170-1176

2015

Volltextzugriff (PDF)

Drug-induced cutaneous vasculitis and anticoagulant-related cutaneous adverse reactions: insights in pathogenesis, clinical presentation, and treatment

Clinics in dermatology, 2020-11, Vol.38 (6), p.613-628

2020

Volltextzugriff (PDF)

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

British journal of dermatology (1951), 2019-02, Vol.180 (2), p.329-337

2019

Volltextzugriff (PDF)

Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts

British journal of dermatology (1951), 2017-03, Vol.176 (3), p.643-649

2017

Volltextzugriff (PDF)

Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization

Allergy (Copenhagen), 2015-07, Vol.70 (7), p.784-794

2015

Volltextzugriff (PDF)

A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry

Rheumatology (Oxford, England), 2020-10, Vol.59 (10), p.2796-2805

2020

Volltextzugriff (PDF)

Paradoxical Reactions to Biologicals in Chronic Inflammatory Systemic Diseases

Deutsches Ärzteblatt international, 2022-02, Vol.119 (6), p.88-95

2022

Volltextzugriff (PDF)

The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection

Journal of pediatric gastroenterology and nutrition, 2019-03, Vol.68 (3), p.334-338

2019

Volltextzugriff (PDF)

To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology, 2015-09, Vol.73 (3), p.420-428.e1

2015

Volltextzugriff (PDF)

In silico assessment of adverse drug reactions and associated mechanisms

Drug discovery today, 2016-01, Vol.21 (1), p.58-71

2016

Volltextzugriff (PDF)

Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2020-01, Vol.18 (1), p.257-258

2020

Volltextzugriff (PDF)

Cutaneous Adverse Events During Treatment of Chronic Inflammatory Rheumatic Conditions With Tumor Necrosis Factor Antagonists: Study Using the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases

Arthritis care & research (2010), 2013-12, Vol.65 (12), p.2024-2031

2013

Volltextzugriff (PDF)

Useful message in choosing optimal biological agents for patients with autoimmune arthritis

Biochemical pharmacology, 2019-07, Vol.165, p.99-111

2019

Volltextzugriff (PDF)

1 – 25 von 80.915

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78.608)

Publikationsform

Sprache

12 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

n.n

Thema

Science & Technology
(75.675)
Biological And Medical Sciences
(75.661)
Life Sciences & Biomedicine
(74.916)
Humans
(73.723)
Medical Sciences
(71.544)
Female
(54.074)
Male
(52.260)
Middle Aged
(38.836)
Risk Factors
(37.914)
Adult
(36.608)
Aged
(28.345)
Time Factors
(28.257)
Pharmacology. Drug Treatments
(16.121)
Adolescent
(12.757)
Treatment Outcome
(12.657)
Animals
(10.638)
Retrospective Studies
(10.617)
Surgery
(10.149)
Oncology
(10.008)
Aged, 80 And Over
(9.465)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(80.809)
Journals@Ovid Complete
(51.978)
Ingenta
(45.897)
EZB Electronic Journals Library
(37.661)
IngentaConnect Journals
(24.068)
Elsevier ScienceDirect Journals
(23.065)
Publisher
(19.617)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(14.958)
Wiley Online Library
(14.634)
Wiley Online Library
(12.741)
Springer Online Journals
(7.808)
Oxford Journals
(7.450)
Oxford Journals 2020 Medicine
(6.487)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(6.120)
JSTOR
(3.819)
Springer Nature - Connect here FIRST to enable access
(3.002)
BMJ Journals
(2.861)
BMJ Journals Archiv - DFG Nationallizenzen
(2.791)
Nexis Uni
(2.615)
Taylor & Francis:Master (3349 titles)
(2.266)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)